Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Current Leases (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Current Leases for 5 consecutive years, with $665082.0 as the latest value for Q1 2023.

  • On a quarterly basis, Current Leases fell 2.76% to $665082.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $665082.0, a 2.76% decrease, with the full-year FY2022 number at $577198.0, down 6.98% from a year prior.
  • Current Leases was $665082.0 for Q1 2023 at Marker Therapeutics, up from $577198.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $738389.0 in Q2 2022 to a low of $189791.0 in Q1 2019.
  • A 5-year average of $441696.5 and a median of $473077.0 in 2021 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 134.5% in 2020, then decreased 15.67% in 2022.
  • Marker Therapeutics' Current Leases stood at $204132.0 in 2019, then skyrocketed by 90.46% to $388792.0 in 2020, then surged by 59.59% to $620490.0 in 2021, then dropped by 6.98% to $577198.0 in 2022, then grew by 15.23% to $665082.0 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Current Leases are $665082.0 (Q1 2023), $577198.0 (Q4 2022), and $490449.0 (Q3 2022).